康华生物
(300841)
| 流通市值：60.67亿 | | | 总市值：64.84亿 |
| 流通股本：1.22亿 | | | 总股本：1.30亿 |
| 报告期 | 2026-09-30 | 2026-06-30 | 2026-03-31 | 2025-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 884,662,834.85 | 538,353,610.55 | 172,451,817.58 | 1,165,000,864.15 |
| 营业收入 | 884,662,834.85 | 538,353,610.55 | 172,451,817.58 | 1,165,000,864.15 |
| 二、营业总成本 | 638,998,861.42 | 373,656,732.19 | 140,114,140.64 | 895,140,732.6 |
| 营业成本 | 96,269,583.49 | 55,101,151.48 | 15,556,376.7 | 92,797,651.6 |
| 税金及附加 | 12,315,733.81 | 8,201,158.17 | 4,423,443.75 | 10,257,759.34 |
| 销售费用 | 372,605,592.5 | 215,581,747.95 | 74,350,518.57 | 557,553,219.81 |
| 管理费用 | 89,597,135.42 | 55,832,163.01 | 26,137,056.88 | 120,645,222.39 |
| 研发费用 | 70,297,395.57 | 40,495,186.45 | 20,447,722.13 | 118,389,362.42 |
| 财务费用 | -2,086,579.37 | -1,554,674.87 | -800,977.39 | -4,502,482.96 |
| 其中:利息费用 | 385,792.05 | 342,424.57 | 349,076.96 | 3,681,028.2 |
| 其中:利息收入 | 2,523,739.83 | 1,937,307.63 | 1,175,245.04 | 8,149,793.62 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | 8,393,891.67 | 4,558,765.9 | 1,901,607 | -3,572,949.83 |
| 加:投资收益 | 2,850,745.18 | 2,518,787.98 | 51,888.92 | 5,433,347.58 |
| 资产处置收益 | - | - | - | -8,912.45 |
| 资产减值损失(新) | -6,430,998.26 | -6,309,973.61 | -3,983,038.6 | -8,089,709.48 |
| 信用减值损失(新) | -5,268,958.01 | -8,881,452.36 | -1,786,610.35 | -11,509,086.35 |
| 其他收益 | 3,581,211.61 | 2,434,140.38 | 1,157,320.52 | 7,757,519.9 |
| 四、营业利润 | 248,789,865.62 | 159,017,146.65 | 29,678,844.43 | 259,870,340.92 |
| 加:营业外收入 | 10,900 | 6,000 | 6,000 | - |
| 减:营业外支出 | 261,975.34 | 142,570.19 | 141,830.79 | 127,132.87 |
| 五、利润总额 | 248,538,790.28 | 158,880,576.46 | 29,543,013.64 | 259,743,208.05 |
| 减:所得税费用 | 30,385,647.06 | 17,731,276.07 | 2,179,596.17 | 39,845,273.01 |
| 六、净利润 | 218,153,143.22 | 141,149,300.39 | 27,363,417.47 | 219,897,935.04 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 218,153,143.22 | 141,149,300.39 | 27,363,417.47 | 219,897,935.04 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 227,266,657.31 | 141,149,300.39 | 27,363,417.47 | 219,897,935.04 |
| 少数股东损益 | -9,113,514.09 | - | - | - |
| 扣除非经常损益后的净利润 | 216,058,013.47 | 134,181,507.15 | 25,259,074.33 | 211,907,992.18 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 1.75 | 1.09 | 0.21 | 1.69 |
| (二)稀释每股收益 | 1.75 | 1.09 | 0.21 | 1.69 |
| 九、综合收益总额 | 218,153,143.22 | 141,149,300.39 | 27,363,417.47 | 219,897,935.04 |
| 归属于母公司股东的综合收益总额 | 227,266,657.31 | 141,149,300.39 | 27,363,417.47 | 219,897,935.04 |
| 归属于少数股东的综合收益总额 | -9,113,514.09 | - | - | - |
| 公告日期 | 2026-10-21 | 2026-08-18 | 2026-04-21 | 2026-04-21 |
| 审计意见(境内) | | | | 标准无保留意见 |